Crystec, trading as CrystecPharma, have developed a unique system which crystallises drugs into novel particles, enhancing the delivery and performance of medicines. Their expert team works with the global pharmaceutical and healthcare industry to solve drug particle formation, formulation and process challenges. With funds raised, they will match grant-funding to continue a project with Chinese partners, as part of the InnovateUK Newton Fund Research and Innovation Bridges Programme
Performance in every particle
We work with clients in the global pharmaceutical and healthcare industry to improve the formulation and efficacy of drugs, to ultimately raise the quality of life for patients. We also develop our own innovative therapies in important areas of unmet clinical need, including women’s health, urology and respiratory disease.
CrystecPharma has extensive experience in pharmaceutical development. Our team have pioneered the application of SCF to pharmaceuticals and consists of acknowledged leaders in relevant fields of science, drug delivery, engineering, scale-up, manufacturing and medicine, underpinned by senior-level pharmaceutical industry and licensing experience.
With funds raised, we will match grant-funding to continue a project with Chinese manufacturers, as part of the InnovateUK Newton Fund Research and Innovation Bridges Programme*, to improve drugs for asthma and COPD. Current medications either aerosolise poorly or are too expensive for widespread use in China, where there is a high rate of respiratory disease, exacerbated by air pollution. With our SCF technology, we can alter the medicine to aerosolise more easily, in more simple and affordable devices. Ultimately it is hoped that this project will lead to improved access to better respiratory medicines for patients in China and the rest of the world.
*The Newton Fund aims to promote the economic development and social welfare of either partner country.
Where will the funds go?
A. Dear Jonathan, thank you for your question. We are already funding a number of core programmes from revenue, including new therapeutic development programmes in urge incontinence, menorrhagia and migraine, for worldwide markets. We would not have the financial bandwidth to take on this project without additional funding support. We are most grateful to Crowd2Fund investors for their support to this project, which will hopefully improve the lives of people suffering from COPD in China.
Back to the top
"Performance in every particle"
powered by Equifax